{
    "clinical_study": {
        "@rank": "72378", 
        "acronym": "PRS", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "description": "Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal"
            }, 
            {
                "arm_group_label": "Rehearsal group", 
                "description": "Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the procedural and clinical benefits of patient\n      specific pre-procedure rehearsal for operators with various experience levels as a tool for\n      optimizing Endovascular Aneurysm Repair (EVAR) procedures."
        }, 
        "brief_title": "Patient-Specific Simulation Used for EVAR Procedure Rehearsal - Evaluation of Clinical Performance With and Without Prior Rehearsal", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infra Renal Aortic Aneurysm", 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Aortic Aneurysm"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. At least 18 years old\n\n          2. Elective patients planned to undergo EVAR procedures with an endograft compatible\n             with the Simbionix PRS.\n\n          3. Computed Tomography Angiography (CTA) scan of the abdominal aorta performed as\n             standard of care.  Sufficient quality/defined protocol.\n\n        Exclusion Criteria:\n\n          1. Subject is below 18 years old\n\n          2. Operator cannot complete the indicated rehearsal and practice.\n\n          3. Patients requiring emergent aneurysm treatment, e.g. trauma or rupture.\n\n          4. Arterial dissection.\n\n          5. Patients with Stage 4 of chronic kidney disease (GFR<30 ml/min/m2).\n\n          6. Patient is indicated for use of snorkels, chimneys, fenestrated or branched graft\n             devices\n\n          7. Pregnant or lactating women.\n\n          8. Off label stent graft use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects admitted for elective endovascular AAA repair will be randomized"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151942", 
            "org_study_id": "PRS-001"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "elective endovascular AAA repair", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "jrundback@airsllp.com", 
                "last_name": "John H. Rundback, MD", 
                "phone": "201-833-7268"
            }, 
            "contact_backup": {
                "email": "barkama@mail.holyname.org", 
                "last_name": "Ravit Barkama, MD", 
                "phone": "201-541-6312"
            }, 
            "facility": {
                "address": {
                    "city": "Teaneck", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07666"
                }, 
                "name": "Holy Name Medical Center"
            }, 
            "investigator": {
                "last_name": "John H. Rundback, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Patient-Specific Simulation Used for Case Rehearsal Prior to EVAR Procedure - Evaluation of Clinical Performance With and Without Prior Rehearsal Using the Procedure Rehearsal Studio. Multi-center Randomized Study", 
        "overall_contact": {
            "email": "erez@simbionix.com", 
            "last_name": "Erez Ben Zvi", 
            "phone": "+972 54 669 0924"
        }, 
        "overall_official": {
            "affiliation": "Holy Name Medical Center", 
            "last_name": "John H. Rundback, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Overall Fluoro time", 
                "safety_issue": "Yes", 
                "time_frame": "Within 4 hr. after EVAR procedure starts"
            }, 
            {
                "measure": "Subjective operator perceived effectiveness of prior procedure rehearsal", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hr. after EVAR procedure starts"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151942"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall contrast use (volume)\nSkin entry radiation dose\nOverall procedure time (from gaining bilateral access until the satisfactory completion of endograft deployment, excluding all adjunctive procedures such as hypogastric embolization, Iliac Percutaneous Transluminal Angioplasty (PTA)/Stenting, sheath removal and hemostasis time)\nProcedural blood loss - number of transfused units\nArterial injury (dissection, perforation, rupture, surgical conversion, embolization, none)", 
                "measure": "Intraprocedural safety measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Within 4 hr. after EVAR procedure starts"
            }, 
            {
                "description": "Comparison of treatment plans based on Customary (normal institutional) technique, following 3D reconstruction, and after simulation procedures.", 
                "measure": "Change in procedure plan", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hr. after EVAR procedure rehearsal starts"
            }, 
            {
                "description": "Number and type of used wires, catheters, stent grafts, additional stent graft components and balloons", 
                "measure": "Adjunctive device utilization", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hr. after EVAR procedure ends"
            }, 
            {
                "description": "Time to cannulate the contralateral gate with a wire.", 
                "measure": "Gate cannulation time", 
                "safety_issue": "Yes", 
                "time_frame": "Within 3 hr. after EVAR procedure starts"
            }, 
            {
                "description": "Anatomy\nAnticipated devices (sizing, tools)\nFluoroscopic Angulations\nCase complexity", 
                "measure": "Similarity of simulation to actual case", 
                "safety_issue": "No", 
                "time_frame": "Within 3 hr. after EVAR procedure ends"
            }, 
            {
                "description": "Overall ease of use\nControls\nImaging\nDevice exchanges\nDevice performance", 
                "measure": "General satisfaction- Subjective experience of simulation experience", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hr. after EVAR procedure ends"
            }, 
            {
                "measure": "Cost analysis", 
                "safety_issue": "No", 
                "time_frame": "Within the first 30 days after the EVAR procedure"
            }, 
            {
                "description": "Successful endograft deployment and absence of type 1 or 3 endoleak", 
                "measure": "Technical/Clinical success rate", 
                "safety_issue": "Yes", 
                "time_frame": "Within the first 30 days after the EVAR procedure"
            }, 
            {
                "measure": "Time of simulator rehearsal", 
                "safety_issue": "No", 
                "time_frame": "Within 3 hr. after EVAR procedure rehearsal ends"
            }, 
            {
                "measure": "Time in ICU", 
                "safety_issue": "Yes", 
                "time_frame": "within 30 days after the EVAR procedure"
            }, 
            {
                "measure": "Overall Length of Stay", 
                "safety_issue": "Yes", 
                "time_frame": "Within 30 days after the EVAR procedure"
            }
        ], 
        "source": "Simbionix US Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Simbionix US Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}